Lanthanum carbonate
- Generic Name
- Lanthanum carbonate
- Brand Names
- Fosrenol
- Drug Type
- Small Molecule
- Chemical Formula
- C3La2O9
- CAS Number
- 587-26-8
- Unique Ingredient Identifier
- 0M78EU4V9H
- Background
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for t...
- Indication
Used to reduce serum phosphate in patients with end stage renal disease (ESRD).
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
Unicycive eyes June FDA verdict for hyperphosphataemia drug
The FDA is reviewing Unicycive Therapeutics' oxylanthanum carbonate (OLC) for hyperphosphataemia in CKD dialysis patients, aiming to improve on current phosphate binder therapy. OLC requires fewer and smaller pills, potentially enhancing patient adherence. A survey highlighted the need for lower pill burden and better compliance. The global hyperphosphataemia market is $2.5 billion, with 75% of patients failing to meet serum phosphorus targets. Unicycive filed OLC under the 505(b)(2) pathway, requiring only three clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath